Dag Heldal

Oslo University Hospital

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Geir E. Tjønnfjord

University of Oslo

Tobias Gedde‐Dahl

University of Oslo

Yngvar Fløisand

Oslo University Hospital

Lorentz Brinch

Oslo University Hospital

Ingunn Dybedal

Oslo University Hospital

T Egeland

Oslo University Hospital

S A Evensen

Haukeland University Hospital

Gunnar Juliusson

Skåne University Hospital

Torstein Egeland

University of Oslo

Ingerid Weum Abrahamsen

Oslo University Hospital

Cooperative Institutions

Oslo University Hospital

University of Oslo

Karolinska Institutet

Karolinska University Hospital

Haukeland University Hospital

Norwegian Cancer Society

European Society of Clinical Microbiology and Infectious Diseases

Lund University

University of Bergen

Rigshospitalet

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Allogen stamcelletransplantasjon hos voksne med akutt lymfoblastisk leukemi

Tidsskrift for Den Norske Laegeforening (2008)

Yngvar Fløisand Lorentz Brinch Ingunn Dybedal Tobias Gedde‐Dahl Dag Heldal

Source

Cite

Citations (1)

Short‐term side effects and attitudes towards second donation: A comparison of related and unrelated haematopoietic stem cell donors

Journal of Clinical Apheresis (2017)

Simon Pahnke Gunnar Larfors Ulla Axdorph Nygell Anne Fischer‐Nielsen Eva Haastrup

Abstract The Nordic Register of Haematopoietic Stem Cell Donors (NRHSD) has registered related and unrelated donors from 10 transplant centres in Sweden, Norway, Finland and Denmark since 1998. We present a prospective, observational study of 1,957 donors, focusing mainly on the differences between related and unrelated donors. Related donors are reported to have more comorbidities, but similar side effects compared with unrelated donors. Side effects after BM or PBSC donation are generally of short duration and in this study no deaths, myocardial infarctions, splenic ruptures, or thromboembolic events are reported. Interestingly, related donors express more hesitancy towards donating again when asked 1 month after donation.

10.1002/jca.21576

Cite

Citations (2)

HLA-DPB1 mismatch reduce relapse and improve survival in T-cell replete unrelated donor allogeneic stem cell transplantation

Bone Marrow Transplantation (2020)

B. Grønvold Maryan Ali Mats Remberger Jonas Mattsson T Egeland

Histocompatibility Testing

Histocompatibility

10.1038/s41409-020-0827-3

Cite

Citations (1)

A randomised study of allogeneic transplantation with stem cells from blood or bone marrow

Bone Marrow Transplantation (2000)

Dag Heldal Geir E. Tjønnfjord Lorentz Brinch D Albrechtsen T Egeland

Hematology

10.1038/sj.bmt.1702422

Cite

Citations (140)

Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia.

Journal of Clinical Oncology (1995)

Gunnar Juliusson Dag Heldal Erik Hippe Michael Hedenus Christer Malm

PURPOSE To evaluate the clinical efficacy and safety of 2-chlorodeoxyadenosine (CdA) when administered by subcutaneous injection to patients with symptomatic hairy cell leukemia (HCL), and to evaluate predictive factors for response. PATIENTS AND METHODS Seventy-three patients were given CdA as a subcutaneous injection once daily for 7 days. Complete remission (CR) required normalized blood counts and the absence of B-ly 7-positive bone marrow cells by flow cytometry. CdA concentrations in plasma following the first injection were analyzed by high-pressure liquid chromatography. RESULTS Fifty-nine patients (81%) achieved a durable CR after one (n = 55) or two courses, and 10 had a partial remission (PR). With a median follow-up duration of 20 months, no patient had a clinical relapse. Neutropenic fever that required intravenous antibiotics occurred in 28 patients (38%). No toxicity at injection sites was observed. Incomplete response was predicted by an elevated lymphocyte count and serum beta 2-microglobulin level, and by a high percentage of hairy cells in the bone marrow. Plasma CdA levels were similar to those achieved from intravenous administration. CONCLUSION Subcutaneous injection of CdA is safe and as effective as continuous infusion without problems associated with the mode of administration. Our schedule simplifies CdA treatment and can be generally recommended.

Cladribine

Subcutaneous injection

Absolute neutrophil count

10.1200/jco.1995.13.4.989

Cite

Citations (105)

Hårcelleleukemi behandlet med cladribin

Tidsskrift for Den Norske Laegeforening (2002)

Waleed Ghanima Dag Heldal Geir E. Tjønnfjord

Source

Cite

Citations (0)

Low‐dose cladribine for symptomatic hairy cell leukaemia

British Journal of Haematology (1995)

Gunnar Juliusson Rodiça Lenkei Geir E. Tjønnfjord Dag Heldal Jan Liliemark

Cladribine is an effective therapy for hairy cell leukaemia (HCL), but the standard regime is frequently complicated by neutropenic fever and prolonged T‐cell depression. We studied 102 patients with active HCL following treatment with various doses of cladribine given for 7 d. Two patients received 1 mg cladribine/m 2 /d without toxicity or effect. Eight subsequent patients received 2 mg cladribine/m 2 /d, and normalized cytopenia as quickly as 94 control patients receiving a standard dose (3.4mg/m 2 or 0.085 mg/kg), with significantly less lymphopenia and a similar complete remission rate.

Cladribine

Cytopenia

Leukopenia

10.1111/j.1365-2141.1995.tb08377.x

Cite

Citations (13)

The CD34⁺ Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Peripheral Blood Stem Cells from Sibling Donors

Clinical Hematology International (2020)

Mats Remberger B. Grønvold Maryan Ali Jonas Mattsson T Egeland

The effect of CD34 + cell dose in allogeneic hematopoietic stem cell transplantation (HSCT) on overall survival (OS) and incidence of acute and chronic graft-versus-host disease (GvHD) has not been established and few studies have been performed.Our single center analysis included 189 patients with hematological malignancies who received peripheral blood stem cell (PBSC) grafts from sibling donors.Myeloablative conditioning was used in 88 cases and 101 received reduced intensity conditioning.The median CD34 + cell dose was 5.6 × 10 6 /kg (0.6-17.0).In the multivariate analysis, a CD34 cell dose of 6-7 × 10 6 /kg was associated with better OS and lower transplant-related mortality (TRM), while a dose of <5 × 10 6 /kg led to increased relapse and reduced chronic GVHD (cGVHD).A high CD34 cell-dose (>6.5 × 10 6 /kg) correlated with less acute GVHD (aGVHD) II-IV.We conclude that the CD34 cell dose has an impact on the outcome of HSCT from sibling donor PBSCs.

10.2991/chi.d.200221.001

Cite

Citations (13)

Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines

Journal of Infection (2017)

Małgorzata Mikulska Diana Averbuch Frédéric Tissot Catherine Cordonnier Murat Akova

Critical appraisal

10.1016/j.jinf.2017.10.009

Cite

Citations (156)

Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies

Cancer Immunology Immunotherapy (2014)